Fundsmith, an investment management firm based in London, has released its annual 2025 investor letter for its “Fundsmith Equity Fund.” A copy of the letter can be downloaded here. The fund focuses on ...

While they might not represent the most exciting field in the biotech space, animal healthcare companies have been a steady, consistent source of growth in what's often a turbulent market. One company ...

IDEXX Laboratories, Inc. (IDXX) is a multinational healthcare company specializing in the development, manufacture, and ...

It notched a beat-and-raise third quarter. It cited innovation and increased customer take-up as reasons for the solid growth it posted during the frame. Idexx published its third-quarter figures well ...

IDEXX Laboratories continues to outperform the S&P 500, driven by strong recurring revenue and a robust customer ecosystem. IDXX delivered a double beat in Q3, with revenue up 13% and EPS up 21%, ...

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 fourth quarter and full year financial results for Monday, February 2, 2026 ...

Baron Funds, an investment management company, released its “Baron Asset Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. US equities ended the quarter higher ...

Achieves first quarter revenue growth of 4% as reported and 5% organic, supported by CAG Diagnostics recurring revenue growth of 3% as reported and 4.5% organic. Organic revenue growth supported by ...

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and ...